Novartis eyes chief executive shake-up in 2018

September 4, 2017

Swiss pharmaceutical giant Novartis said Monday its chief executive for the past seven years, Joseph Jimenez, will step down in 2018, allowing chief medical officer Vasant Narasimhan to take the reins.

Jimenez, who joined Novartis in 2007 and took over as CEO in 2010, had informed the board of directors of his wish to relinquish his leadership position early next year, Novartis said in a statement.

He will step down on January 31, but has agreed to remain available to provide advice and support until he retires from Novartis on August 31, it added.

"Both from a professional and a personal perspective, this is the right moment to hand the leadership reins of the company to Vas," Jimenez said in the statement, pointing to the company's "strong pipeline" and insisting Novartis was "on a strong path for the future."

"On the personal side, after 10 wonderful years in Switzerland, my family is ready to return to Silicon Valley and the US," he said, adding: "I'm confident that Vas will be an excellent successor."

Narasimhan, who will take over as on February 1, joined Novartis in 2005.

The US citizen, who is 41, holds a medical degree and a public policy degree from Harvard, and previously worked for McKinsey & Company.

The married father of two is currently serving as the global head of drug development and chief medical officer at Novartis.

"We anticipate a smooth transition," Joerg Reinhardt, chairman of the Novartis board said in the statement.

Explore further: Novartis to buy back $5 bn in shares

Related Stories

Novartis to buy back $5 bn in shares

January 25, 2017
Swiss pharmaceutical giant Novartis announced Wednesday a $5.0 billion share buyback even though competition from generics ate away at sales and earnings last year.

Novartis Korea executives charged for bribing doctors

August 13, 2016
Prosecutors have indicted the former chief executive of the South Korean unit of Novartis and five other former and current managers over allegations they illegally paid doctors 2.6 billion won ($2.3 million) in return for ...

Roche 'extremely open' to talks with Novartis: report

October 1, 2013
The head of Swiss pharmaceutical giant Roche is open to renewed cooperation with competitor Novartis, he told the Financial Times in an interview published Tuesday.

Novartis chief sees sales dip until mid-2013

October 7, 2012
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Novartis Q4 net profit rebounds to $2.1 billion

January 23, 2013
(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.

Novartis to use Google technology for eye care

July 15, 2014
Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.

Recommended for you

Common use of antipsychotics shown ineffective for delirium in intensive care patients

October 22, 2018
Critically ill patients in intensive care units (ICUs) did not benefit from two antipsychotic drugs used to treat delirium, according to a large clinical trial funded by the National Institute on Aging, part of the National ...

Medicating distress: Risky sedative prescriptions for older adults vary widely

October 18, 2018
Despite years of warnings that older adults shouldn't take sedative drugs that put them at risk of injury and death, a new study reveals how many primary care doctors are still prescribing them, how often, and exactly where.

Medical management of opioid-induced constipation differs from other forms of condition

October 17, 2018
Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association ...

Research assesses geographic distribution of new antibiotics following market introduction

October 16, 2018
There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with ...

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.